Cancer gene therapy with T cell receptors and chimeric antigen receptors

Current Opinion in Pharmacology

Volumn 24, Issue , 2015, Pages 113-118

  Stauss, Hans J ^a   Morris, Emma C ^a   Abken, Hinrich ^b,c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF COLOGNE   (Germany)

^c UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; LYMPHOCYTE ANTIGEN RECEPTOR; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; BINDING AFFINITY; CANCER CELL; CHIMERA; CHRONIC LYMPHATIC LEUKEMIA; CYTOKINE RELEASE; GENE THERAPY; HUMAN; IMMUNOTHERAPY; LYMPHOCYTE DIFFERENTIATION; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR GENE; VIRAL GENE DELIVERY SYSTEM; ANIMAL; METABOLISM; NEOPLASMS;

ANIMALS; ANTIGENS, NEOPLASM; GENETIC THERAPY; HUMANS; NEOPLASMS; RECEPTORS, ANTIGEN; RECEPTORS, ANTIGEN, T-CELL;

EID: 84940947070     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2015.08.006     Document Type: Review

References (53)

1. G.P. Dunn, A.T. Bruce, K.C. Sheehan, V. Shankaran, R. Uppaluri, J.D. Bui, M.S. Diamond, C.M. Koebel, C. Arthur, J.M. White, and et al. A critical function for type I interferons in cancer immunoediting Nat Immunol 6 2005 722 729
2. C.M. Koebel, W. Vermi, J.B. Swann, N. Zerafa, S.J. Rodig, L.J. Old, M.J. Smyth, and R.D. Schreiber Adaptive immunity maintains occult cancer in an equilibrium state Nature 450 2007 903 907
3. H. Matsushita, M.D. Vesely, D.C. Koboldt, C.G. Rickert, R. Uppaluri, V.J. Magrini, C.D. Arthur, J.M. White, Y.S. Chen, L.K. Shea, and et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting Nature 482 2012 400 404
4. S.A. Rosenberg, and N.P. Restifo Adoptive cell transfer as personalized immunotherapy for human cancer Science 348 2015 62 68
5. P. Sharma, and J.P. Allison The future of immune checkpoint therapy Science 348 2015 56 61
6. J.R. Brahmer, S.S. Tykodi, L.Q. Chow, W.J. Hwu, S.L. Topalian, P. Hwu, C.G. Drake, L.H. Camacho, J. Kauh, K. Odunsi, and et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer N Engl J Med 366 2012 2455 2465
7. F.S. Hodi, S.J. O'Day, D.F. McDermott, R.W. Weber, J.A. Sosman, J.B. Haanen, R. Gonzalez, C. Robert, D. Schadendorf, J.C. Hassel, and et al. Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med 363 2010 711 723
8. S.L. Topalian, F.S. Hodi, J.R. Brahmer, S.N. Gettinger, D.C. Smith, D.F. McDermott, J.D. Powderly, R.D. Carvajal, J.A. Sosman, M.B. Atkins, and et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer N Engl J Med 366 2012 2443 2454
9. M.M. Gubin, X. Zhang, H. Schuster, E. Caron, J.P. Ward, T. Noguchi, Y. Ivanova, J. Hundal, C.D. Arthur, W.J. Krebber, and et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens Nature 515 2014 577 581
10. R.S. Herbst, J.C. Soria, M. Kowanetz, G.D. Fine, O. Hamid, M.S. Gordon, J.A. Sosman, D.F. McDermott, J.D. Powderly, S.N. Gettinger, and et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients Nature 515 2014 563 567
11. T. Powles, J.P. Eder, G.D. Fine, F.S. Braiteh, Y. Loriot, C. Cruz, J. Bellmunt, H.A. Burris, D.P. Petrylak, S.L. Teng, and et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer Nature 515 2014 558 562
12. P.C. Tumeh, C.L. Harview, J.H. Yearley, I.P. Shintaku, E.J. Taylor, L. Robert, B. Chmielowski, M. Spasic, G. Henry, V. Ciobanu, and et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance Nature 515 2014 568 571
13. M.E. Dudley, J.R. Wunderlich, P.F. Robbins, J.C. Yang, P. Hwu, D.J. Schwartzentruber, S.L. Topalian, R. Sherry, N.P. Restifo, A.M. Hubicki, and et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes Science 298 2002 850 854
14. E. Tran, S. Turcotte, A. Gros, P.F. Robbins, Y.C. Lu, M.E. Dudley, J.R. Wunderlich, R.P. Somerville, K. Hogan, C.S. Hinrichs, and et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer Science 344 2014 641 645
15. S. Stevanovic, L.M. Draper, M.M. Langhan, T.E. Campbell, M.L. Kwong, J.R. Wunderlich, M.E. Dudley, J.C. Yang, R.M. Sherry, U.S. Kammula, and et al. Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells J Clin Oncol 33 2015 1543 1550
16. T.N. Schumacher, and R.D. Schreiber Neoantigens in cancer immunotherapy Science 348 2015 69 74
17. G. Gross, T. Waks, and Z. Eshhar Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity Proc Natl Acad Sci U S A 86 1989 10024 10028
18. T. Stanislawski, R.H. Voss, C. Lotz, E. Sadovnikova, R.A. Willemsen, J. Kuball, T. Ruppert, R.L. Bolhuis, C.J. Melief, C. Huber, and et al. Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer Nat Immunol 2 2001 962 970
19. D.A. Williams, and A.J. Thrasher Concise review: lessons learned from clinical trials of gene therapy in monogenic immunodeficiency diseases Stem Cells Transl Med 3 2014 636 642
20. P.B. Hackett, D.A. Largaespada, K.C. Switzer, and L.J. Cooper Evaluating risks of insertional mutagenesis by DNA transposons in gene therapy Transl Res 161 2013 265 283
21. S.S. Kenderian, M. Ruella, O. Shestova, M. Klichinsky, V. Aikawa, J.J. Morrissette, J. Scholler, D. Song, D.L. Porter, M. Carroll, and et al. CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia Leukemia 2015
22. R.J. Brentjens, M.L. Davila, I. Riviere, J. Park, X. Wang, L.G. Cowell, S. Bartido, J. Stefanski, C. Taylor, M. Olszewska, and et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia Sci Transl Med 5 2013 177ra138
23. M. Kalos, B.L. Levine, D.L. Porter, S. Katz, S.A. Grupp, A. Bagg, and C.H. June T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia Sci Transl Med 3 2011 95ra73
24. D.W. Lee, J.N. Kochenderfer, M. Stetler-Stevenson, Y.K. Cui, C. Delbrook, S.A. Feldman, T.J. Fry, R. Orentas, M. Sabatino, N.N. Shah, and et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial Lancet 385 2015 517 528
25. S.L. Maude, N. Frey, P.A. Shaw, R. Aplenc, D.M. Barrett, N.J. Bunin, A. Chew, V.E. Gonzalez, Z. Zheng, S.F. Lacey, and et al. Chimeric antigen receptor T cells for sustained remissions in leukemia N Engl J Med 371 2014 1507 1517
26. D.L. Porter, B.L. Levine, M. Kalos, A. Bagg, and C.H. June Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia N Engl J Med 365 2011 725 733
27. L.A. Johnson, R.A. Morgan, M.E. Dudley, L. Cassard, J.C. Yang, M.S. Hughes, U.S. Kammula, R.E. Royal, R.M. Sherry, J.R. Wunderlich, and et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen Blood 114 2009 535 546
28. R.A. Morgan, M.E. Dudley, J.R. Wunderlich, M.S. Hughes, J.C. Yang, R.M. Sherry, R.E. Royal, S.L. Topalian, U.S. Kammula, N.P. Restifo, and et al. Cancer regression in patients after transfer of genetically engineered lymphocytes Science 314 2006 126 129
29. P.F. Robbins, R.A. Morgan, S.A. Feldman, J.C. Yang, R.M. Sherry, M.E. Dudley, J.R. Wunderlich, A.V. Nahvi, L.J. Helman, C.L. Mackall, and et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1 J Clin Oncol 29 2011 917 924
30. H.M. Finney, A.D. Lawson, C.R. Bebbington, and A.N. Weir Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product J Immunol 161 1998 2791 2797
31. A. Hombach, A. Wieczarkowiecz, T. Marquardt, C. Heuser, L. Usai, C. Pohl, B. Seliger, and H. Abken Tumor-specific T cell activation by recombinant immunoreceptors: CD3 zeta signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3 zeta signaling receptor molecule J Immunol 167 2001 6123 6131
32. A.A. Hombach, and H. Abken Costimulation by chimeric antigen receptors revisited the T cell antitumor response benefits from combined CD28-OX40 signalling Int J Cancer 129 2011 2935 2944
33. C. Carpenito, M.C. Milone, R. Hassan, J.C. Simonet, M. Lakhal, M.M. Suhoski, A. Varela-Rohena, K.M. Haines, D.F. Heitjan, S.M. Albelda, and et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains Proc Natl Acad Sci U S A 106 2009 3360 3365
34. M.C. Milone, J.D. Fish, C. Carpenito, R.G. Carroll, G.K. Binder, D. Teachey, M. Samanta, M. Lakhal, B. Gloss, G. Danet-Desnoyers, and et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo Mol Ther 17 2009 1453 1464
35. A.A. Hombach, M. Chmielewski, G. Rappl, and H. Abken Adoptive immunotherapy with redirected T cells produces CCR7-cells that are trapped in the periphery and benefit from combined CD28-OX40 costimulation Hum Gene Ther 24 2013 259 269
36. M. Chmielewski, A.A. Hombach, and H. Abken CD28 cosignalling does not affect the activation threshold in a chimeric antigen receptor-redirected T-cell attack Gene Ther 18 2011 62 72
37. A.A. Hombach, V. Schildgen, C. Heuser, R. Finnern, D.E. Gilham, and H. Abken T cell activation by antibody-like immunoreceptors: the position of the binding epitope within the target molecule determines the efficiency of activation of redirected T cells J Immunol 178 2007 4650 4657
38. R.D. Guest, R.E. Hawkins, N. Kirillova, E.J. Cheadle, J. Arnold, A. O'Neill, J. Irlam, K.A. Chester, J.T. Kemshead, D.M. Shaw, and et al. The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigens J Immunother 28 2005 203 211
39. A. Hombach, C. Heuser, M. Gerken, B. Fischer, K. Lewalter, V. Diehl, C. Pohl, and H. Abken T cell activation by recombinant FcepsilonRI gamma-chain immune receptors: an extracellular spacer domain impairs antigen-dependent T cell activation but not antigen recognition Gene Ther 7 2000 1067 1075
40. D. Moritz, and B. Groner A spacer region between the single chain antibody- and the CD3 zeta-chain domain of chimeric T cell receptor components is required for efficient ligand binding and signaling activity Gene Ther 2 1995 539 546
41. D. Moritz, W. Wels, J. Mattern, and B. Groner Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells Proc Natl Acad Sci U S A 91 1994 4318 4322
42. C.J. Cohen, Y.F. Li, M. El-Gamil, P.F. Robbins, S.A. Rosenberg, and R.A. Morgan Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond Cancer Res 67 2007 3898 3903
43. J. Kuball, M.L. Dossett, M. Wolfl, W.Y. Ho, R.H. Voss, C. Fowler, and P.D. Greenberg Facilitating matched pairing and expression of TCR chains introduced into human T cells Blood 109 2007 2331 2338
44. C.J. Cohen, Y. Zhao, Z. Zheng, S.A. Rosenberg, and R.A. Morgan Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability Cancer Res 66 2006 8878 8886
45. D. Sommermeyer, and W. Uckert Minimal amino acid exchange in human TCR constant regions fosters improved function of TCR gene-modified T cells J Immunol 184 2010 6223 6231
46. E. Provasi, P. Genovese, A. Lombardo, Z. Magnani, P.Q. Liu, A. Reik, V. Chu, D.E. Paschon, L. Zhang, J. Kuball, and et al. Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer Nat Med 18 2012 807 815
47. J.D. Stone, D.T. Harris, and D.M. Kranz TCR affinity for p/MHC formed by tumor antigens that are self-proteins: impact on efficacy and toxicity Curr Opin Immunol 33c 2015 16 22
48. S. Thomas, S.A. Xue, C.R. Bangham, B.K. Jakobsen, E.C. Morris, and H.J. Stauss Human T cells expressing affinity-matured TCR display accelerated responses but fail to recognize low density of MHC-peptide antigen Blood 118 2011 319 329
49. S. Valitutti, S. Muller, M. Cella, E. Padovan, and A. Lanzavecchia Serial triggering of many T-cell receptors by a few peptide-MHC complexes Nature 375 1995 148 151
50. M. Ahmadi, J.W. King, S.A. Xue, C. Voisine, A. Holler, G.P. Wright, J. Waxman, E. Morris, and H.J. Stauss CD3 limits the efficacy of TCR gene therapy in vivo Blood 118 2011 3528 3537
51. B.J. Cameron, A.B. Gerry, J. Dukes, J.V. Harper, V. Kannan, F.C. Bianchi, F. Grand, J.E. Brewer, M. Gupta, G. Plesa, and et al. Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells Sci Transl Med 5 2013 197ra103
52. R.A. Morgan, N. Chinnasamy, D. Abate-Daga, A. Gros, P.F. Robbins, Z. Zheng, M.E. Dudley, S.A. Feldman, J.C. Yang, R.M. Sherry, and et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy J Immunother 36 2013 133 151
53. K. Simon-Keller, A. Paschen, A.A. Hombach, P. Strobel, J.M. Coindre, S.B. Eichmuller, A. Vincent, S. Gattenlohner, F. Hoppe, I. Leuschner, and et al. Survivin blockade sensitizes rhabdomyosarcoma cells for lysis by fetal acetylcholine receptor-redirected T cells Am J Pathol 182 2013 2121 2131